Blueprint Medicines (BPMC) Announces Earnings Results, Misses Estimates By $0.16 EPS

Blueprint Medicines (NASDAQ:BPMC) released its earnings results on Wednesday. The biotechnology company reported ($1.23) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.07) by ($0.16), Bloomberg Earnings reports. Blueprint Medicines had a negative net margin of 437.83% and a negative return on equity of 43.11%. The company had revenue of $1.63 million during the quarter, compared to analysts’ expectations of $5.28 million. During the same quarter last year, the business posted ($0.75) earnings per share. The company’s revenue for the quarter was down 78.8% on a year-over-year basis.

Shares of Blueprint Medicines (BPMC) opened at $81.84 on Wednesday. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.02. Blueprint Medicines has a 52-week low of $32.43 and a 52-week high of $92.00. The company has a market capitalization of $3,492.37, a PE ratio of -24.00 and a beta of 1.16.

A number of analysts have weighed in on the company. Raymond James Financial set a $82.00 price target on Blueprint Medicines and gave the company a “buy” rating in a research note on Sunday, December 10th. Cowen restated a “buy” rating on shares of Blueprint Medicines in a research note on Friday, November 10th. Canaccord Genuity restated a “buy” rating and issued a $80.00 price target (up from $66.00) on shares of Blueprint Medicines in a research note on Wednesday, November 1st. BidaskClub cut Blueprint Medicines from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. Finally, Goldman Sachs Group raised their price target on Blueprint Medicines from $82.00 to $99.00 and gave the company a “buy” rating in a research note on Monday, December 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $84.20.

In other news, Director Daniel Lynch sold 12,500 shares of Blueprint Medicines stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $80.42, for a total transaction of $1,005,250.00. Following the sale, the director now owns 174,342 shares in the company, valued at $14,020,583.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kate Haviland sold 6,775 shares of Blueprint Medicines stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $74.93, for a total value of $507,650.75. Following the sale, the insider now owns 12,649 shares in the company, valued at approximately $947,789.57. The disclosure for this sale can be found here. Insiders have sold 36,775 shares of company stock worth $2,822,601 in the last quarter. Insiders own 3.40% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Blueprint Medicines by 57.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 680 shares in the last quarter. Rockefeller Financial Services Inc. acquired a new stake in shares of Blueprint Medicines during the third quarter worth about $160,000. Ameritas Investment Partners Inc. increased its position in shares of Blueprint Medicines by 68.9% during the second quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock worth $173,000 after purchasing an additional 1,391 shares in the last quarter. QS Investors LLC acquired a new stake in shares of Blueprint Medicines during the fourth quarter worth about $173,000. Finally, First Mercantile Trust Co. acquired a new stake in shares of Blueprint Medicines during the fourth quarter worth about $183,000. Institutional investors and hedge funds own 89.28% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Blueprint Medicines (BPMC) Announces Earnings Results, Misses Estimates By $0.16 EPS” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/21/blueprint-medicines-bpmc-announces-earnings-results-misses-estimates-by-0-16-eps.html.

About Blueprint Medicines

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Earnings History for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply